Bio-pharmaceutical company Omeros Corporation has announced pricing for a public offering of 3,478,260 shares of its common stock to be $11.5 per share.

Omeros is expected to raise gross proceeds of $40m through the offering, which will be used for general corporate purposes such as research and development (R&D) expenses for its clinical OMS721 programme, new drug applications, repayment of debt, and other capital expenditures.

Cytocentrics, Inc has raised $9.18m of its planned $21.82m in venture financing by issuing equity securities to ten investors.

Specialist pharmaceutical company Recro Pharma, Inc has announced plans to raise $14.9m through an underwritten public offering of 1,986,666 shares of its common stock, priced at $7.5 per share.

"Cytocentrics, Inc has raised $9.18m of its planned $21.82m in venture financing by issuing equity securities to ten investors."

Recro plansto invest the funds in ongoing Phase III pivotal clinical trial and safety studies of injectable meloxicam and for meeting other capital expenditures.

Advaxis, Inc plans to raise $30.3m through a private placement of 2,244,443 shares of its common stock, priced at $13.5 per share.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bio-pharmaceutical company Tioma Therapeutics, Inc has raised $86m in series A venture financing round.

Tioma plans to use the funds to expand its antibody portfolio and primarily its lead drug candidate, an anti-CD47 immune checkpoint inhibitor.